On August 4, 2025, Pyxis Oncology, Inc. reported updates on its Phase 1 clinical trial for micvotabart pelidotin, confirming maximum patient enrollment numbers. This revision reflects industry standards and aligns with previously stated guidance regarding head and neck squamous cell carcinoma patient enrollment.